高级检索
当前位置: 首页 > 详情页

MiR-34b-3p represses cell proliferation, cell cycle progression and cell apoptosis in non-small-cell lung cancer (NSCLC) by targeting CDK4

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Department of Thoracic Surgery, China– Japan Friendship Hospital, Beijing, China [2]Department of Cell Biology and Genetics, College of Life Sciences, Nankai University, Tianjin, China [3]Department of Emergency, Peking University Third Hospital, Beijing, China
出处:
ISSN:

关键词: apoptosis CDK4 cell cycle cell proliferation miR-34b-3p miRNA high throughput NSCLC

摘要:
Lung cancer is the most common incident cancer, with a high mortality worldwide, and non-small-cell lung cancer (NSCLC) accounts for approximately 85% of cases. Numerous studies have shown that the aberrant expression of microRNAs (miRNAs) is associated with the development and progression of cancers. However, the clinical significance and biological roles of most miRNAs in NSCLC remain elusive. In this study, we identified a novel miRNA, miR-34b-3p, that suppressed NSCLC cell growth and investigated the underlying mechanism. miR-34b-3p was down-regulated in both NSCLC tumour tissues and lung cancer cell lines (H1299 and A549). The overexpression of miR-34b-3p suppressed lung cancer cell (H1299 and A549) growth, including proliferation inhibition, cell cycle arrest and increased apoptosis. Furthermore, luciferase reporter assays confirmed that miR-34b-3p could bind to the cyclin-dependent kinase 4 (CDK4) mRNA 3'-untranslated region (3'-UTR) to suppress the expression of CDK4 in NSCLC cells. H1299 and A549 cell proliferation inhibition is mediated by cell cycle arrest and apoptosis with CDK4 interference. Moreover, CDK4 overexpression effectively reversed miR-34-3p-repressed NSCLC cell growth. In conclusion, our findings reveal that miR-34b-3p might function as a tumour suppressor in NSCLC by targeting CDK4 and that miR-34b-3p may, therefore, serve as a biomarker for the diagnosis and treatment of NSCLC.

语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验 3 区 细胞生物学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 细胞生物学 3 区 医学:研究与实验
JCR分区:
出版当年[2017]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q2 CELL BIOLOGY
最新[2023]版:
Q2 CELL BIOLOGY Q2 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2017版] 出版当年五年平均[2013-2017] 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者单位: [1]Department of Thoracic Surgery, China– Japan Friendship Hospital, Beijing, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Thoracic Surgery, China– Japan Friendship Hospital, Beijing, China [*1]Department of Thoracic Surgery, China‐Japan Friendship Hospital, Beijing, 100029, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)